 John Hamner
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 8 | 2009 | 151 | 0.860 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 954 | 0.780 |
Why?
| | Interferon-beta | 7 | 2010 | 89 | 0.650 |
Why?
| | Gastric Outlet Obstruction | 1 | 2019 | 9 | 0.640 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2019 | 9 | 0.640 |
Why?
| | Duodenal Neoplasms | 1 | 2019 | 21 | 0.630 |
Why?
| | Carcinoma, Lobular | 1 | 2019 | 47 | 0.620 |
Why?
| | Urologic Neoplasms | 1 | 2017 | 26 | 0.550 |
Why?
| | Hepatectomy | 1 | 2017 | 212 | 0.500 |
Why?
| | Neoplasms, Second Primary | 1 | 2015 | 106 | 0.450 |
Why?
| | Pancreaticoduodenectomy | 1 | 2015 | 158 | 0.450 |
Why?
| | Neovascularization, Pathologic | 5 | 2010 | 295 | 0.410 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2015 | 269 | 0.390 |
Why?
| | Breast Neoplasms | 2 | 2019 | 2127 | 0.390 |
Why?
| | Liver Neoplasms | 1 | 2017 | 637 | 0.380 |
Why?
| | Adenocarcinoma | 2 | 2015 | 891 | 0.370 |
Why?
| | Genetic Therapy | 3 | 2008 | 288 | 0.320 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2010 | 808 | 0.310 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 879 | 0.280 |
Why?
| | Hydroxamic Acids | 1 | 2008 | 88 | 0.280 |
Why?
| | Boronic Acids | 1 | 2007 | 37 | 0.280 |
Why?
| | Lymphedema | 1 | 2007 | 23 | 0.270 |
Why?
| | Melanoma | 3 | 2018 | 729 | 0.260 |
Why?
| | Pyrazines | 1 | 2007 | 87 | 0.260 |
Why?
| | Mice, SCID | 9 | 2010 | 350 | 0.250 |
Why?
| | Soft Tissue Neoplasms | 1 | 2007 | 111 | 0.250 |
Why?
| | Skin Neoplasms | 3 | 2018 | 824 | 0.250 |
Why?
| | Pain, Postoperative | 1 | 2007 | 233 | 0.230 |
Why?
| | Antineoplastic Agents | 5 | 2007 | 2045 | 0.230 |
Why?
| | Combined Modality Therapy | 3 | 2015 | 1198 | 0.210 |
Why?
| | Head and Neck Neoplasms | 2 | 2018 | 542 | 0.200 |
Why?
| | Aged | 8 | 2019 | 21997 | 0.160 |
Why?
| | Stem Cells | 3 | 2009 | 574 | 0.160 |
Why?
| | Radiation Tolerance | 2 | 2010 | 98 | 0.160 |
Why?
| | Disease-Free Survival | 2 | 2017 | 644 | 0.150 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1280 | 0.150 |
Why?
| | Cell Line, Tumor | 8 | 2010 | 3186 | 0.150 |
Why?
| | Tumor Burden | 4 | 2018 | 286 | 0.140 |
Why?
| | In Vitro Techniques | 3 | 2009 | 1085 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 2 | 2010 | 219 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4882 | 0.120 |
Why?
| | Erlotinib Hydrochloride | 1 | 2015 | 70 | 0.120 |
Why?
| | Postoperative Complications | 1 | 2007 | 2472 | 0.120 |
Why?
| | Bone Neoplasms | 2 | 2009 | 229 | 0.120 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2015 | 36 | 0.120 |
Why?
| | Adenoviridae | 4 | 2008 | 192 | 0.120 |
Why?
| | Deoxycytidine | 1 | 2015 | 164 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2017 | 470 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 72 | 0.110 |
Why?
| | Thyroid Neoplasms | 1 | 2018 | 312 | 0.110 |
Why?
| | Stomach Neoplasms | 1 | 2014 | 97 | 0.110 |
Why?
| | Immunotherapy | 1 | 2018 | 590 | 0.110 |
Why?
| | Prognosis | 3 | 2018 | 3766 | 0.100 |
Why?
| | Humans | 19 | 2019 | 129144 | 0.100 |
Why?
| | Female | 9 | 2019 | 68494 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2018 | 574 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2014 | 251 | 0.090 |
Why?
| | Mice | 11 | 2010 | 16905 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2018 | 14450 | 0.090 |
Why?
| | Middle Aged | 7 | 2018 | 31050 | 0.090 |
Why?
| | Male | 13 | 2018 | 63456 | 0.090 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2010 | 10 | 0.080 |
Why?
| | Oxygen Consumption | 2 | 2010 | 672 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2009 | 24 | 0.080 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2008 | 67 | 0.070 |
Why?
| | Cyclophosphamide | 1 | 2008 | 232 | 0.070 |
Why?
| | Subcutaneous Tissue | 1 | 2007 | 22 | 0.070 |
Why?
| | Bortezomib | 1 | 2007 | 45 | 0.070 |
Why?
| | Stockings, Compression | 1 | 2007 | 5 | 0.070 |
Why?
| | Skin Care | 1 | 2007 | 21 | 0.070 |
Why?
| | Topotecan | 1 | 2007 | 12 | 0.070 |
Why?
| | Random Allocation | 1 | 2008 | 346 | 0.070 |
Why?
| | Probability | 1 | 2008 | 305 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1554 | 0.070 |
Why?
| | Animals | 11 | 2010 | 35286 | 0.070 |
Why?
| | Neoplasm Transplantation | 4 | 2007 | 256 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 607 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2018 | 10192 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 58 | 0.060 |
Why?
| | Drainage | 1 | 2007 | 164 | 0.060 |
Why?
| | Glioma | 1 | 2010 | 347 | 0.060 |
Why?
| | Bone Density Conservation Agents | 1 | 2006 | 70 | 0.060 |
Why?
| | Clinical Protocols | 1 | 2007 | 254 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2008 | 4056 | 0.060 |
Why?
| | Analgesics | 1 | 2007 | 188 | 0.060 |
Why?
| | Imidazoles | 1 | 2006 | 234 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 187 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1202 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2010 | 2368 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1197 | 0.060 |
Why?
| | Pain Measurement | 1 | 2007 | 506 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2010 | 1363 | 0.060 |
Why?
| | Risk Factors | 1 | 2017 | 9740 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1833 | 0.050 |
Why?
| | United States | 5 | 2018 | 13825 | 0.050 |
Why?
| | Exercise Therapy | 1 | 2007 | 412 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2008 | 712 | 0.050 |
Why?
| | Genetic Vectors | 3 | 2008 | 312 | 0.050 |
Why?
| | Chronic Disease | 1 | 2007 | 1714 | 0.040 |
Why?
| | Adult | 5 | 2018 | 35469 | 0.040 |
Why?
| | Neurons | 1 | 2008 | 1493 | 0.040 |
Why?
| | Bevacizumab | 2 | 2010 | 128 | 0.040 |
Why?
| | Transduction, Genetic | 2 | 2009 | 129 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 2008 | 202 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2018 | 320 | 0.030 |
Why?
| | California | 1 | 2018 | 400 | 0.030 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2017 | 107 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2017 | 164 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 851 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2007 | 7037 | 0.030 |
Why?
| | Drug Delivery Systems | 2 | 2008 | 332 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1208 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 202 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2010 | 757 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1544 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1266 | 0.030 |
Why?
| | Neoplasms | 1 | 2007 | 2442 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 1964 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3140 | 0.020 |
Why?
| | Disease Progression | 2 | 2009 | 2622 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1895 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1869 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 12385 | 0.020 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2010 | 39 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2010 | 76 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2010 | 192 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2010 | 234 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2635 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 419 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 5408 | 0.020 |
Why?
| | Angiopoietin-1 | 1 | 2007 | 11 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5044 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 385 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 145 | 0.020 |
Why?
| | Dependovirus | 1 | 2007 | 62 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1304 | 0.020 |
Why?
| | Pressure | 1 | 2007 | 237 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 529 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 6541 | 0.010 |
Why?
| | Cell Movement | 1 | 2007 | 944 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2008 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2775 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4075 | 0.010 |
Why?
| | Hypoxia | 1 | 2007 | 1084 | 0.010 |
Why?
| | Cytokines | 1 | 2007 | 2012 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3071 | 0.010 |
Why?
| | Apoptosis | 1 | 2006 | 2491 | 0.010 |
Why?
|
|
Hamner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|